Guardion Health Sciences, Inc. completes registration with SEC, becomes a Public Reporting Company

  SAN DIEGO, CA - 01/04/2017 (PRESS RELEASE JET)

On December 27, 2016, the U.S Securities and Exchange Commission declared effective the Registration Statement on Form S-1

(No. 333-209488) of Guardion Health Sciences, Inc. (“Guardion” or the “Company”). Accordingly, Guardion is now a public reporting company.

Michael Favish, the founder and CEO of Guardion, commented, “This news brings to a close a year of accomplishment for Guardion. We received recognition in several highly

respected ocular health publications. Our trademark registrations have been issued for Guardion®, MapcatSF® and Lumega-Z®. On November 8, 2016, the U.S. Patent and

Trademark Office issued patent number 9,486,136 for our MapcatSF® medical device.” Mr. Favish continued, “In the upcoming year, we intend to begin the evaluation of

potential acquisitions of synergistic and ‘value added’ technologies that may be interested in becoming part of a public company. We will seek to continue to raise new

capital through the sale of our equity securities to fund our operations. We also intend to take steps in 2017 to create a public market for our stock, and we are continuing to

interview prospective market makers.”

Mr. Favish concluded, “Our focus will be on age-related eye disease and vision performance in 2017. We believe that Guardion is poised for significant growth, as we

continue to address the growing need for early detection and intervention with respect to age-related macular degeneration and other retinal diseases. With the combination of

our existing intellectual property portfolio, and strategically selected additional technologies, Guardion is well-positioned to achieve its immediate and longer term

objectives.”

This press release does not constitute an offer of our securities for sale, which can only be made by means of definitive offering documents.

For information regarding investment opportunities, or for interested industry parties, please contact Vincent Roth, General Counsel, at vroth@guardionhealth.com or (858)

605-9055 Ext 208.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food

product that addresses a depleted macular protective pigment, which is a known risk factor for causing age-related macular degeneration (“AMD”), as well as computer vision

syndrome (“CVS”). Guardion Health Sciences, Inc. has also developed a proprietary medical device that accurately measures the macular pigment density.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein contain forward-looking statements within the meaning of

Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown

risks and uncertainties that may individually or materially impact the matters herein for a variety of reasons that are outside the control of the Company, including, but not limited

to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products. Readers

are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking

statements contained herein. Readers are urged to read the risk factors set forth in the Company’s recently effective Registration Statement on Form S-1 (No. 333-209488), as

well as the financial statements included therein. The Registration Statement on Form S-1 is available from the SEC’s website, www.sec.gov, or without charge from the

Company. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or

otherwise. Actual results could differ materially from those anticipated in these forward looking statements, if new information becomes available in the future.

564505v.2